Key result
Higher circulating IL-6 levels were significantly associated with worse SF-36 quality of life subscale scores for bodily pain, vitality, and mental health in PAH patients (all P < 0.01).
Why the study?
Although inflammation is linked to symptoms in many chronic illnesses, the association between inflammatory markers such as IL-6 and tumor necrosis factor-α and quality of life-related symptoms had not been established in pulmonary arterial hypertension.
Observational (n=62)
Answers are grounded in this paper and cite their sources.
Higher circulating levels of inflammatory markers, particularly IL-6, are associated with worse quality of life domains in patients with pulmonary arterial hypertension.
Rationale Inflammation is associated with symptoms in many chronic illnesses; however, this link has not been established in pulmonary arterial hypertension. Objectives The objective of this study was to investigate the association between inflammatory markers and quality of life–related symptoms in patients with pulmonary arterial hypertension. We hypothesized that higher circulating IL-6 and tumor necrosis factor-α levels would be associated with worse quality of life–related symptoms. Methods We performed a secondary analysis using baseline and 3-month assessments of 62 subjects in a clinical trial of aspirin and simvastatin to determine the association between plasma IL-6 and tumor necrosis factor-α levels and the Medical Outcomes Study Short Form-36 subscales (pain, vitality, mental health). Measurements and Main Results The mean age was 49.7 ± 13.4 years; 87% were female. Higher IL-6 levels were significantly associated with lower Medical Outcomes Study Short Form-36 subscale scores, indicating worse bodily pain, vitality, and mental health (all P < 0.01). Higher tumor necrosis factor-α levels were significantly associated with increased bodily pain, but better mental health scores. Conclusions IL-6 and tumor necrosis factor-α levels are associated with certain quality of life domains in patients with pulmonary arterial hypertension. Clinical trial registered with www.clinicaltrials.gov (NCT00384865).
No takes yet. Share an insight, caveat, or question.
Matura et al. (2015) conducted an observational in Pulmonary arterial hypertension (n=62). Plasma IL-6 and tumor necrosis factor-α levels was evaluated on Medical Outcomes Study Short Form-36 subscales (bodily pain, vitality, mental health) (p=<0.01). Higher circulating IL-6 levels were significantly associated with worse SF-36 quality of life subscale scores for bodily pain, vitality, and mental health in PAH patients (all P < 0.01).
Synapse has enriched 10 related papers. Consider them for comparative context: